On Monday, October 7, shares of the biotech company Scholar Rock soared close to 362% following the announcement that its lead candidate, apitegromab, a treatment for spinal muscular atrophy (SMA), had demonstrated clinically significant results in the final, phase III trial. Currently, there are only three approved drugs for this…